Q3: Subsequent Infusion

*Combined Follow Up
In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, subsequent infusions are always reported on the Post-TED (2450) Form and the question is disabled on the Cellular Therapy Essential Data Follow-Up (4100) Form.

Question 3: Did the recipient receive a subsequent infusion?

Indicate if the recipient received a subsequent infusion during the reporting period. Subsequent infusions include transplant, cellular therapy, gene therapy, DLI, and ‘boost’ (autologous or allogeneic).

If Yes, complete the Indication for CIBMTR Data Reporting (2814).

For more information on infusion types, review Appendix D: How to Distinguish Infusion Types.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
Q3	1/23/2026	Modify	Combined Follow Up blue box updated: Combined Follow Up and Subsequent Infusion: In scenarios where a cellular therapy was given after an HCT and this form is now being completed based on the subsequent cellular therapy date, subsequent infusions are always reported on the Post-TED (2450) Form and the question is disabled on the Cellular Therapy Essential Data Follow-Up (4100) Form. When both HCT and cell therapy forms are being completed, the subsequent infusion question is disabled on the Cellular Therapy Essential Data Follow-Up (4100) form and should be answered on the Post-TED (2450).	Updated for clarification

Copyright © 2004-2026 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.